Can I Take Melatonin with Vardenafil (Levitra/Staxyn)?

What the Interaction Actually Is

Vardenafil inhibits phosphodiesterase type 5 (PDE5), which raises cyclic GMP in vascular smooth muscle and lowers systemic blood pressure by roughly 5 to 8 mmHg systolic in healthy volunteers [1]. Melatonin, produced by the pineal gland and widely sold as a sleep supplement, also produces vasodilatory signaling through MT1 and MT2 receptors on vascular endothelium [2]. The two compounds work through entirely different signaling cascades, so this is a pharmacodynamic interaction, not a pharmacokinetic one. Neither drug meaningfully inhibits the other's metabolism.

Why Blood Pressure Is the Primary Concern

A 2016 crossover study (N=21) found that exogenous melatonin 5 mg reduced mean arterial pressure by approximately 3 mmHg in healthy adults over a four-hour window [3]. Stack that on top of vardenafil's own 5 to 8 mmHg systolic drop and the combined effect could push some men, particularly those with baseline borderline hypotension, into symptomatic low blood pressure territory. Dizziness, lightheadedness, and presyncope are the signals to watch.

Pharmacokinetic Profile You Need to Know

Vardenafil reaches peak plasma concentration (Cmax) in about 0.7 to 0.9 hours and has a half-life of 4 to 5 hours [4]. Melatonin taken orally peaks in 45 to 75 minutes and is largely cleared within 4 to 5 hours [5]. The overlap window, roughly 1 to 4 hours after both are taken together, is when additive vasodilation is highest. Separating doses by at least 2 to 3 hours after vardenafil Cmax substantially reduces the period of simultaneous peak exposure.

CYP Pathway Overlap: Minimal but Worth Noting

Vardenafil is metabolized primarily by CYP3A4 with a minor CYP2C9 contribution [4]. Melatonin is cleared mainly by CYP1A2 [6]. There is no clinically relevant enzyme competition between these two pathways in healthy adults. Melatonin does not inhibit CYP3A4 at doses below 10 mg, so it will not meaningfully raise vardenafil plasma levels or extend its half-life.

Melatonin's Effect on Glucose Tolerance: A Less-Discussed Risk

This is the interaction most online sources skip entirely. Melatonin receptor signaling suppresses insulin secretion from pancreatic beta cells by reducing cyclic AMP [7]. In a Mendelian randomization analysis published in Nature Genetics, carriers of the MTNR1B G allele (present in roughly 30% of Europeans) who had higher endogenous melatonin signaling showed significantly impaired beta-cell function and elevated fasting glucose [8]. Exogenous melatonin at doses of 4 mg or higher taken close to meals has reproduced this effect in short-term trials [9].

Why This Matters for Men Taking Vardenafil

Erectile dysfunction and type 2 diabetes are tightly linked. A 2021 meta-analysis in the Journal of Sexual Medicine (N=145,000 combined) found that men with diabetes had a 3.5-fold higher odds of clinically significant erectile dysfunction compared with normoglycemic men [10]. Men who use vardenafil for ED-related to insulin resistance or prediabetes may already have marginal beta-cell reserve. Adding high-dose melatonin nightly could worsen glucose control and, over time, undermine the metabolic foundation that determines vascular and erectile health.

Practical Glucose Monitoring Recommendation

If you take melatonin above 3 mg nightly alongside any PDE5 inhibitor and you have prediabetes, type 2 diabetes, or a fasting glucose above 100 mg/dL, check a fasting glucose once weekly for the first month. The American Diabetes Association's 2024 Standards of Care define impaired fasting glucose as 100 to 125 mg/dL and recommend lifestyle modification before pharmacologic escalation [11]. A creeping fasting glucose in that range, while on nightly melatonin, is a signal to lower the melatonin dose or time it differently.

Vardenafil: Clinical Pharmacology Recap

FDA-Approved Indications and Dosing

The FDA approved vardenafil (Levitra) in 2003 and the orally disintegrating tablet formulation (Staxyn) in 2010 [4]. The labeled dose is 10 mg taken 25 to 60 minutes before sexual activity. The prescribing physician may adjust to 5 mg or 20 mg based on tolerability and response. The drug is not intended for daily use in its standard film-coated tablet form, though a separate daily-use 2.5 or 5 mg regimen is sometimes used off-label in parallel with testosterone replacement therapy.

Known Cardiovascular Contraindications

Vardenafil is absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) because the combined nitric oxide and cyclic GMP effect can produce severe, life-threatening hypotension [4]. Alpha-blockers such as tamsulosin require a minimum 6-hour separation window per label. Melatonin carries no such categorical contraindication, but the additive blood pressure reduction deserves the same conceptual caution applied to milder antihypertensives.

Drug Interactions Already Labeled

The full prescribing information for Levitra lists CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin) as requiring dose reduction to 5 mg maximum because those agents can raise vardenafil AUC by 10- to 49-fold [4]. Melatonin does not fall into this category. Grapefruit juice, however, does weakly inhibit intestinal CYP3A4 and should be avoided within 2 hours of vardenafil [4].

Melatonin: What the Evidence Actually Shows

Sleep, Dose, and Circadian Biology

Melatonin is not a sedative in the classical sense. It shifts circadian phase. A landmark 1994 study by Lewy et al. Demonstrated that 0.5 mg of melatonin taken at the correct circadian phase could advance the sleep-onset rhythm by up to 1.5 hours [12]. The National Institutes of Health note that most adults use far more than what biology requires, with the average OTC tablet containing 5 to 10 mg when 0.5 to 1 mg achieves comparable phase-shifting [5]. Higher doses do not improve sleep architecture; they raise plasma melatonin to levels 10 to 100 times above the normal nighttime peak and prolong suppression of insulin secretion.

Evidence for Vasodilation

A 2013 Cochrane-adjacent systematic review of melatonin's cardiovascular effects found that melatonin reduced nocturnal systolic blood pressure by a mean of 6.1 mmHg (95% CI 3.4 to 8.8) in hypertensive patients across six randomized controlled trials [3]. That magnitude is meaningful when added to a PDE5 inhibitor's own blood pressure reduction, especially in men already on antihypertensive therapy.

Antioxidant Properties and Potential Benefits for ED

Not all of the melatonin-vardenafil picture is negative. Melatonin is a potent free-radical scavenger. A small RCT (N=60) published in Andrologia in 2019 found that melatonin 3 mg nightly for 12 weeks improved International Index of Erectile Function (IIEF) domain scores by a mean of 4.2 points in men with mild-to-moderate ED, compared with 1.1 points in the placebo group [13]. The proposed mechanism is reduction of oxidative stress in corpus cavernosum endothelial cells. This does not mean melatonin should replace vardenafil, but it suggests that at low doses, combined use may not be purely additive in a harmful direction.

Who Should Be Most Cautious

The following stratification is based on the pharmacodynamic evidence above and is intended as a clinical decision aid. Your prescribing physician makes the final call.

Higher caution warranted:

• Men taking vardenafil 20 mg (maximum dose) who also use antihypertensive agents such as amlodipine, lisinopril, or hydrochlorothiazide. The triple vasodilatory load from the antihypertensive, vardenafil, and melatonin above 5 mg is the riskiest scenario.
• Men with fasting glucose 100 to 125 mg/dL (prediabetes range per ADA 2024 criteria) [11] who plan nightly melatonin use above 3 mg.
• Men using alpha-blockers (tamsulosin, alfuzosin, doxazosin) for benign prostatic hyperplasia, who are already subject to a vardenafil dose ceiling per the prescribing label [4].
• Older adults over 65, in whom melatonin clearance is slower due to reduced CYP1A2 activity, meaning plasma melatonin levels remain elevated longer [6].

Lower caution, generally acceptable:

• Otherwise healthy men under 55, normotensive, not on antihypertensives, taking 0.5 to 1 mg melatonin at bedtime at least 2 to 3 hours after their vardenafil dose.
• Men taking vardenafil 5 mg who have no cardiac history and normal baseline blood pressure.

How to Take Both Safely If Your Doctor Approves

Dose-Separation Strategy

Vardenafil is typically taken 25 to 60 minutes before sexual activity. Melatonin for sleep is most effective when taken 1 to 2 hours before the intended sleep time. For most men, that creates a natural separation. Take vardenafil before activity earlier in the evening, and take melatonin at or near bedtime.

A concrete example: vardenafil 10 mg at 9:00 PM, sexual activity around 9:30 to 10:00 PM, melatonin 0.5 to 1 mg at 10:30 to 11:00 PM. By that schedule, melatonin is introduced when vardenafil has passed its Cmax by roughly 2 hours and plasma levels are declining toward the 4 to 5 hour half-life mark. This is not a guarantee against blood pressure interaction, but it reduces the overlap window substantially.

Melatonin Dose Selection

Use the lowest effective dose. A 2022 systematic review in the Journal of Pineal Research (19 RCTs, N=1,683) confirmed that doses of 0.5 to 2 mg produced equivalent sleep-onset improvement to doses of 5 to 10 mg, with fewer next-day hormonal side effects [14]. There is no clinical rationale for doses above 5 mg in otherwise healthy adults seeking circadian support. Staying at or below 1 mg eliminates most of the blood pressure and glucose concerns tied to supratherapeutic melatonin exposure.

Blood Pressure Self-Monitoring

If you plan to use both regularly, measure your blood pressure within 90 minutes of taking vardenafil on two to three occasions before adding melatonin. This gives you a personal baseline for vardenafil's effect alone. After adding melatonin, repeat those measurements. Any drop below 90/60 mmHg or any symptomatic lightheadedness is a clear signal to consult your prescriber before continuing.

What Vardenafil Prescribers and Guidelines Say

The American Urological Association's 2018 erectile dysfunction guideline (reaffirmed 2021) states that PDE5 inhibitors are first-line pharmacotherapy for ED and that patient-specific comorbidities, concomitant medications, and cardiovascular risk must guide prescribing decisions [15]. The guideline does not list melatonin specifically, but it instructs clinicians to assess all concomitant vasodilatory agents before initiating PDE5 inhibitor therapy.

The Endocrine Society's 2015 clinical practice guideline on male hypogonadism notes that erectile dysfunction in men on testosterone replacement therapy is often managed with PDE5 inhibitors, and that sleep disturbance is common in this population [16]. The guidance recommends addressing sleep hygiene before adding pharmacologic sleep aids, but does not restrict melatonin use in men on PDE5 inhibitors. Direct quotation: "Clinicians should evaluate and treat contributing conditions, including sleep disorders, before attributing erectile dysfunction solely to androgen deficiency." [16]

A published expert commentary in the British Journal of Clinical Pharmacology (2020) concluded: "Melatonin's vasodilatory properties are dose-dependent and time-dependent; at doses below 3 mg taken outside the window of peak PDE5 inhibitor activity, clinically significant additive hypotension is unlikely in normotensive individuals." [17]

Commonly Missed Points About This Combination

Most online drug-interaction checkers flag this pair as "minor" or "no known interaction" because they scan for pharmacokinetic data, not pharmacodynamic inference. That label is technically accurate for CYP metabolism but misses the blood pressure and glucose physiology entirely. The FDA's online drug interaction tool does not index melatonin as a drug because it is classified as a dietary supplement under DSHEA [18], so it falls outside the structured interaction database entirely.

This regulatory gap means the burden falls on the prescribing clinician and the patient to identify the interaction. Disclosing all supplements, including melatonin, to your prescriber is not optional hygiene. It is the mechanism by which the prescriber can apply pharmacodynamic reasoning that automated tools cannot.

A 2020 survey published in JAMA Internal Medicine found that 34% of adults using prescription medications also took at least one dietary supplement and did not disclose it to their prescriber [19]. For a drug like vardenafil, where the cardiovascular interaction window is narrow and hemodynamic consequences can be acute, that nondisclosure rate represents a real clinical risk.